"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ... Nordisk markets its blockbuster semaglutide (GLP-1) medicines as ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Her doctor prescribed the cheaper, generic version of the weight-loss drug after her insurer refused to cover Zepbound, the brand-name version made by Eli Lilly. DeBenedetto, now 43, tells me she ...

Eli Lilly applied for HSE reimbursement of Mounjaro for diabetes ... Tirzepatide is administered subcutaneously once-weekly and is delivered in a ‘KwikPen’, a pre-filled, multi-dose pen. In the ...

Though they have different names, they’re essentially the same medication created and produced by the company Eli Lilly. Both use tirzepatide ... Mounjaro comes in a pre-filled pen that’s easy to use, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

provided 47% greater relative weight loss compared to Wegovy (semaglutide). - Eli Lilly Q4 Presentation In Q4 2024, Eli Lilly's revenue grew 45%, driven by Mounjaro and Zepbound, the company's ...

This indicates there remains much potential in the molecules used as the basis for obesity drugs -- semaglutide for Novo Nordisk, and tirzepatide in the case of Eli Lilly. Waxing bullish about the ...

Eli Lilly and ... seems to be in agreement — that Lilly's results today have come a long way towards putting those doubts to bed. Tirzepatide and semaglutide have generated a total of ~$40bn ...